Back to search results

Long-term Safety of Admilparant for Pulmonary Fibrosis

This study is looking at the long-term safety of a drug called Admilparant (BMS-986278) for people with pulmonary fibrosis (scarring of the lungs). You can join this study if you have already completed a previous study (IM027068 or IM0271015) where you received Admilparant. The main goal is to see how many participants experience side effects, serious side effects, or side effects that lead them to stop taking the drug over a period of up to 100 weeks. The study plans to enroll 2277 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 2277 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 100 weeks to track side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Not Yet Recruiting
PHASE3All AgesInterventionalTreatment
Bristol-Myers Squibb
~2,380 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:BMS-986278

At a glance

Recruiting sites
0 of 275 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Measured over Up to Week 100
+6 more outcomes measured

Conditions

Pulmonary Fibrosis

Explore related trials

Idiopathic Pulmonary FibrosisPulmonary FibrosisLYSOPHOSPHATIDIC ACID RECEPTOR 1

Where it's being run

275 sites across 143 states
Spain11
China10
South Korea10
France8
India7
Tokyo7
Japan7
Peru6

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation.
Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015.
Exhibit symptoms of heart failure at rest.
History of lung reduction surgery or lung transplant.
Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy.

What this trial measures

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs)Up to Week 100
  • Number of Participants With Serious Adverse Events (SAEs)Up to Week 100
  • Number of Participants With AEs leading to DiscontinuationUp to Week 100
  • Number of Participants With AEs leading to DeathsUp to Week 100
  • Number of Participants With Clinically Significant Laboraty AbnormalitiesUp to Week 100
  • Number of Participants With Clinically Significant Electocardiogram (ECG) AbnormalitiesUp to Week 100
  • Number of Participants With Clinically Significant Vital Sign AbnormalitiesUp to Week 100